{"id":"W2334974730","doi":"10.1097/coc.0b013e31820dbdcc","title":"A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma","year":2011,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; Medicine; Gemcitabine; Carboplatin; Internal medicine; Chemotherapy; Oncology; Progressive disease; Regimen; Nasopharyngeal carcinoma; Erlotinib Hydrochloride; Cisplatin; Gastroenterology; Cancer; Radiation therapy; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001779753,0.001490643,0.002163415,0.0003813503,0.0004079702,0.001038807,0.0009219096,0.001198953,0.002924405],"category_scores_gemma":[0.001224884,0.0005771102,0.001008735,0.0004194581,0.0008840094,0.0008966086,0.0003333258,0.002942761,0.0006761662],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007945849,"about_ca_system_score_gemma":0.001268398,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006120889,"about_ca_topic_score_gemma":0.001604386,"domain_scores_codex":[0.9995849,0.0002031441,0.00002642495,0.00008284382,0.00002935465,0.00007338814],"domain_scores_gemma":[0.9991424,0.0001587067,0.0002077131,0.00009449518,0.00004966314,0.0003469684],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8861291,0.03145845,0.006146058,0.0005507336,0.0008139723,0.0002341024,0.0002129542,0.001191323,0.02005746,0.0001110656,0.001822157,0.05127259],"study_design_scores_gemma":[0.7410864,0.2474319,0.00748266,0.00002797208,0.0003001631,0.0002197569,0.00003637102,0.001009702,0.001442533,0.00007030925,0.000872776,0.00001929693],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955978,0.001333093,0.000237854,0.0003012457,0.0001011951,0.001244884,0.000367106,0.0000533735,0.0007634927],"genre_scores_gemma":[0.9933275,0.0009754156,0.0008211066,0.0005012034,0.0001436324,0.001782156,0.001152266,0.00001674798,0.001279918],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002924405,"threshold_uncertainty_score":0.009783149,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08404970786032828,"score_gpt":0.4195930154508751,"score_spread":0.3355433075905468,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}